TCRX TScan Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why TCRX matters now
TScan Therapeutics, Inc. (TCRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.06 with -15.87% on the session and $64.7M in market capitalization; recent performance reads 1-month -4.48% and YTD -8.00%.
The latest financial table shown here is Q1 2026, with revenue of $982.0K, net income of $-28.7M, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -222.4%.
The latest indexable market news headline is "TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $7.50; recent insider activity includes Klencke Barbara filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.23
P/S
6.15
EV/EBITDA
-0.17
DCF Value
$-4.12
FCF Yield
-222.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.4%
Operating Margin
-1408.7%
Net Margin
-1360.6%
ROE
-91.9%
ROA
-61.5%
ROIC
-67.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $982.0K | $-28.7M | $-0.22 |
| Q4 2025 | $2.6M | $-23.0M | $-0.18 |
| FY 2025 | $10.3M | $-129.8M | $-1.00 |
| Q3 2025 | $2.5M | $-35.7M | $-0.28 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$7.50
Target (Median)
$7.50
Target Range
$3.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.03
TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers. The company's pipeline features programs like TSC-100 and TSC-101, which are engineered to address blood cancers by clearing remnant leukemia cells and averting disease recurrence following hematopoietic stem cell transplantation. Additionally, TScan is advancing multiple candidates, including TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, targeting solid tumor indications. Beyond its oncology efforts, the company is also engaged in vaccine development for infectious agents, such as SARS-CoV-2. TScan has formed a strategic collaboration and licensing arrangement with Novartis Institutes for BioMedical Research, Inc., aimed at pinpointing novel cancer-specific antigens derived from the T cells of particular cancer patients. Founded in 2018, TScan Therapeutics, Inc. operates from its headquarters in Waltham, Massachusetts.